JAK2 V617F mutations occur in over 95% patients with PV and approximately 50% of patients with ET or PMF, and these entities are associated with different allele burden levels [22–25], with ET harboring the lowest JAK2 allele burden as compared to PV and PMF [26,27]. The gene discussed is JAK2; the disease is essential thrombocythemia.